Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7923747 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Combination niraparib and abiraterone for HRR-altered metastatic castration-resistant prostate cancer.
Future Oncol
December 2024
Department of Medical Oncology, BC Cancer Agency, Vancouver, Canada.
Metastatic prostate cancer remains incurable. Though significant progress has been made in the field, the search for agents that improve outcomes for patients is ongoing. Several clinical trials have explored the benefit of combining PARP inhibitors (PARPi) with androgen receptor pathway inhibitors (ARPIs) for metastatic castrate resistant prostate cancer (mCRPC), especially those cancers with alterations in homologous recombination repair (HRR) genes.
View Article and Find Full Text PDFDirect and Indirect Costs of Breast Cancer and Associated Implications: A Systematic Review.
Adv Ther
July 2024
Oncology Business Unit, AstraZeneca, Gaithersburg, MD, 20878, USA.
Article Synopsis
- Breast cancer is the most common cancer globally, significantly impacting societies and economies, prompting a review of its economic burden in the US, Canada, Australia, and various Western European countries.
- The review analyzed published studies since 2017 focusing on cost data related to breast cancer, assessing the quality and completeness of these studies, and categorizing costs by country, cancer stage, and resource type.
- Out of 53 studies reviewed, the majority came from the US and Canada, with a focus on healthcare/medical costs, indicating a higher prevalence of early-stage cancer studies compared to metastatic cases.
Emergency research without prior consent in the United States, Canada, European Union and United Kingdom: How regulatory differences affect study design and implementation in cardiac arrest trials.
Resusc Plus
March 2024
Division of Critical Care Medicine, Department of Anesthesiology and Critical Care Medicine, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Aim: A major barrier to performing cardiac arrest trials is the requirement for prospective informed consent, which is often infeasible during individual medical emergencies. In an effort to improve outcomes, some governments have adopted legislation permitting research without prior consent (RWPC) in these circumstances. We aimed to outline key differences between legislation in four Western locations and explore the effects of these differences on trial design and implementation in cardiac arrest research.
View Article and Find Full Text PDFPre-operative partial breast irradiation: revolutionizing radiation treatment for women with early stage breast cancer.
Ann Breast Surg
December 2022
Department of Radiation Oncology, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
Partial breast irradiation (PBI) has been increasingly accepted as a suitable component of breast conservation in the management of patients with early stage breast cancer, however the majority of existing studies have focused on the use of adjuvant or intra-operative techniques. Several early stage studies have more recently shown that PBI can be safely used in the pre-operative setting. Early data show similar local control without evidence of increased toxicity or worsening cosmesis, as compared to postoperative PBI or standard whole breast irradiation.
View Article and Find Full Text PDFCharacterization of Oncology Clinical Trials Using Germline Genetic Data.
JAMA Netw Open
November 2022
Cancer Data Science Laboratory, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
Importance: The recent successes of poly-ADP ribose polymerase (PARP) inhibitors and belzutifan support germline genetic data as an exciting, accessible source for biomarkers in cancer treatment. This study hypothesizes, however, that most oncology clinical trials using germline data largely prioritize BRCA1/2 as biomarkers and PARP inhibitors as therapy.
Objective: To characterize past and ongoing oncology trials that use germline data.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!